The purpose of the Histopathology Facility (HF) is to facilitate research conducted by investigators with peer-reviewed funding at FCCC by providing them with technical processing of cells and tissues as well as helping in the interpretation of results. The Facility's Technicians and Pathologist play a major support role in numerous research projects at the Center and their contributions have been and continue to be of paramount importance in the establishment and characterization of human cancer and other disease models. The Facility prepares, processes, and assists in evaluating tissues derived from experimental protocols developed by investigators with peer-reviewed funding. Most of the projects involve animal models of human cancer that require complex histological and/or cytological processing to determine morphological alterations, as well as to localize cancer-relevant gene products. The most frequently utilized services of the Facility include: laboratory animal autopsy, fixation, embedding and sectioning of paraffin-embedded tissues (7,000-8,000 per year), unstained paraffin sections for immunohistocnemistry (IHC) and LCM (10,000-14,000 per year), cryomicrotomy (100-200 per year), special stains (500-700 per year), immunohistochemistry (2,500-3,500 per year), in situ hybridization (100-200 per year), autoradiography (100-200 per year), digital microphotography (1,000-2,500 per year), and interpretative histopathology (7,000-10,000 HE and IHC slides signed-out per year). During the last CCSG funding cycle we have seen a significant increase in all services rendered as exemplified by the doubling in number of embedded and sectioned tissues (110% increase) and in the immunohistochemical work (120% increase). Furthermore, during 2000-2004 we implemented new technology such as tissue microarray sectioning and a Web-based Experimental Histopathology database. The Histopathology Facility also provides support to the Laboratory Animal Health Facility in quality control and animal health monitoring activities, as well as processing support to the Tumor Bank and the Research Cytogenetics and Laser Capture Microdissection Facilities. The HF is used by 33 investigators with peer-reviewed funding in 10 different Programs from all three Divisions. Eighty-nine percent (86%) of its use is for studies supported with peer-reviewed funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-45
Application #
7467225
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
45
Fiscal Year
2007
Total Cost
$227,937
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Fareed, Muhammad M; Eldib, Ahmed; Weiss, Stephanie E et al. (2018) A treatment planning comparison between a novel rotating gamma system and robotic linear accelerator based intracranial stereotactic radiosurgery/radiotherapy. Phys Med Biol 63:035029
Bleicher, Richard J (2018) Timing and Delays in Breast Cancer Evaluation and Treatment. Ann Surg Oncol 25:2829-2838
Bai, Tian; Chanda, Ashis Kumar; Egleston, Brian L et al. (2018) EHR phenotyping via jointly embedding medical concepts and words into a unified vector space. BMC Med Inform Decis Mak 18:123
Mehrazin, Reza; Dulaimi, Essel; Uzzo, Robert G et al. (2018) The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. Ther Adv Urol 10:3-10
Tang, Baiqing; Lee, Hyung-Ok; An, Serim S et al. (2018) Specific Targeting of MTAP-Deleted Tumors with a Combination of 2'-Fluoroadenine and 5'-Methylthioadenosine. Cancer Res 78:4386-4395
Fang, Carolyn Y; Tseng, Marilyn (2018) Ethnic density and cancer: A review of the evidence. Cancer 124:1877-1903
Malik, R; Luong, T; Cao, X et al. (2018) Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2. Matrix Biol :
Giri, Veda N; Obeid, Elias; Hegarty, Sarah E et al. (2018) Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling. Prostate 78:879-888
Anari, Fern; O'Neill, John; Choi, Woonyoung et al. (2018) Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol 1:54-60
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739

Showing the most recent 10 out of 1280 publications